Evaluation of Perioperative Celecoxib for Hip Arthroscopy

Overview

Celecoxib is commonly used for perioperative pain control for certain orthopaedic procedures. It has been shown to be successful in assisting in pain control for knee arthroscopy. It has not previously been studied in hip arthroscopy. This is a double blinded randomized controlled trial to determine the efficacy of celecoxib in perioperative pain control for hip arthroscopy.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: January 2016

Detailed Description

This study examines the efficacy of perioperative dose of celecoxib in pain management after hip arthroscopy. Perioperative administration of celecoxib has been shown to improve pain control after knee arthroscopy, but this has not yet been studied in the hip. In this study, patients are randomized to receive either 400mg celecoxib or placebo 1 hour prior to undergoing hip arthroscopy surgery. Postoperatively, patients are monitored for pain on the VAS scale, narcotic use, and meeting discharge criteria. The study will enroll 100 patients. Patients are approached for informed consent on the day of surgery. Pain scores, narcotic use, and time to discharge in the celecoxib group are compared to the placebo group.

Interventions

  • Drug: Celecoxib
    • Received 400mg celecoxib prior to surgery
  • Drug: placebo

Arms, Groups and Cohorts

  • Experimental: Intervention
    • Received 400mg celecoxib prior to surgery
  • Placebo Comparator: Placebo
    • Received placebo pill prior to surgery

Clinical Trial Outcome Measures

Primary Measures

  • Visual Analog Score for Pain (VAS) in the Immediate Post Operative Period
    • Time Frame: Pre operative on day of surgery, immediately following OR close, 1 hr post operatively, 2 hrs post operatively
    • The pain VAS is a uni dimensional measure of pain intensity. It is a continuous scale comprised of a 0-10 pain rating. A score of 0 indicates no pain while a score of 10 would indicate extreme pain.
  • Total Narcotic Consumption in the Post Anesthesia Care Unit (PACU)
    • Time Frame: duration of PACU stay,immediate post op period up to a maximum of 4 hours postoperatively
    • Monitored consumption of narcotic medications following surgery, measured in morphine equivalents
  • Time to Discharge Following Surgery
    • Time Frame: time from OR to discharge, up to a maximum of 6 hours postoperatively
    • Total time to discharge from OR close following surgery, measured in minutes

Participating in This Clinical Trial

Inclusion Criteria

  • All patients who are undergoing a hip arthroscopy procedure at Northwestern Memorial Hospital with Dr. Michael Terry. Exclusion Criteria:

  • Pregnant women and any patient under the age of 18 years.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 89 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Northwestern University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Michael Terry, Associate Professor – Northwestern University
  • Overall Official(s)
    • Michael Terry, MD, Principal Investigator, Northwestern University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.